Robert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the evaluation of ONT-380, an oral HER2-specific inhibitor, for the treatment of patents with HER2-positive metastatic breast cancer.
Robert L. Kirkman, MD
Advertisement
Articles by Robert L. Kirkman, MD
Dr. Robert Kirkman, the CEO of Oncothyreon, on the Combination of PX-866 and Docetaxel
Advertisement
Latest Updated Articles
Dr. Kirkman on the Combination of PX-866 and DocetaxelJune 27th 2012
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
5